Rebecca Dabora, Ph.D. has served as Chief Development Officer since April 2024, having served as the company's Chief Technical Officer since May of 2023. Dr. Dabora leads the Technical Operations, Program Management and Leadership, and Research and Translational Medicine groups. She is a Chemistry, Manufacturing and Controls (CMC) expert with 30+ years of experience in the development of clinical and commercial stage biopharmaceutical products. Dr. Dabora has served in executive roles on both a permanent and interim basis, leading the technical operations function in several companies, including Adagio (now Invivyd, Inc.), Aspyrian Therapeutics, SwanBio Therapeutics, and others. Previous industry affiliations include Merck, Biogen and Invivyd, among others. For more than 15 years, Dr. Dabora was an independent consultant providing CMC strategic, technical, operational, and regulatory support. Over the course of her career, she has worked for more than 90 companies on the development or commercialization of over 140 biopharmaceutical products encompassing a diverse range of expression technologies and manufacturing platforms. Dr. Dabora received her Ph.D. from MIT in Biochemical Engineering and her B.A. in Biochemistry, magna cum laude, from Bowdoin College. She is an avid perennial gardener and enjoys the challenge of Zone 4 gardening in Vermont.